Reuters logo
BRIEF-Nicox provides clinical and regulatory update for NCX 4251 in blepharitis
January 5, 2017 / 6:43 AM / 9 months ago

BRIEF-Nicox provides clinical and regulatory update for NCX 4251 in blepharitis

Jan 5 (Reuters) - Nicox SA :

* Provides clinical and regulatory update for NCX 4251 in blepharitis

* Pre-IND meeting on NCX 4251 with FDA completed

* Phase 2 expected to start Q4 2017

* Subject to IND filing and acceptance, co plans to initiate this phase 2 clinical trial during the fourth quarter of 2017 and expects the trial to take approximately 1 year to complete

* Approval of a new drug application (NDA) for NCX 4251 on or before July 1, 2021 would trigger a milestone payment of up to 10 million dollars in co’s shares to former shareholders of Aciex Therapeutics, Inc Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below